Clinical Trials Directory

Trials / Completed

CompletedNCT04489953

Comparison of Treatment Failure Criteria in HIV-Infected Children in Uganda

Optimizing Antiretroviral Treatment Switch in HIV-Infected Ugandan Children

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
133 (actual)
Sponsor
MU-JHU CARE · Academic / Other
Sex
All
Age
1 Year – 12 Years
Healthy volunteers
Accepted

Summary

The main goal was to compare clinical and immunological versus clinical, immunological plus viral load criteria for switching to second-line ART by comparing 48 week treatment outcomes, including survival rates, viral suppression, failure to thrive, and AIDS-defining illnesses for treatment experienced children randomized to two switching criteria.

Detailed description

The overall goal of the study was aimed at determining whether the use of the current WHO criteria alone (clinical and immunologic) to define treatment failure as the trigger for switching to second-line antiretroviral therapy leads to poorer 6 month and 12 month treatment outcomes when compared to combining clinical and immunologic parameters with viral load (VL) monitoring. In addition the study aimed at obtaining plasma samples from treatment experienced children, for future resistance testing. The results of this study may help guide WHO and national pediatric ART programs on the need for routine VL monitoring for children initiating HAART in resource limited settings, where virologic tests including resistance testing are not readily available or affordable.

Conditions

Interventions

TypeNameDescription
OTHERViral LoadFor the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time

Timeline

Start date
2013-05-01
Primary completion
2017-01-16
Completion
2017-01-16
First posted
2020-07-28
Last updated
2020-07-28

Source: ClinicalTrials.gov record NCT04489953. Inclusion in this directory is not an endorsement.